Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has granted a positive opinion recommending Jardiance empagliflozin for the treatment of adults with chronic kidney disease CKD Boehringer Ingelheim and Eli Lilly and Company NYSE LLY announced today.1
Boehringer Ingelheim and Zealand Pharma AS Nasdaq ZEAL today announced additional data demonstrating superior efficacy with survodutide also known as BI 456906 versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1
ROSEMONT, Ill., June 22, 2023 /PRNewswire/ -- The American Academy of Dermatology, with critical support from Boehringer Ingelheim, and powered by OM1's data aggregation system and its PhenOM™ artificial intelligence
/PRNewswire/ -- The American Academy of Dermatology, with critical support from Boehringer Ingelheim, and powered by OM1's data aggregation system and its...
BI 456906 activates the GLP-1 and glucagon receptors that help to control metabolic function, and could potentially offer clinically relevant benefits for those living with obesity or overweight without type 2 diabetes.